270 related articles for article (PubMed ID: 16160002)
1. Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications.
Joy SV; Scates AC; Bearelly S; Dar M; Taulien CA; Goebel JA; Cooney MJ
Ann Pharmacother; 2005 Oct; 39(10):1693-9. PubMed ID: 16160002
[TBL] [Abstract][Full Text] [Related]
2. A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy.
Casellini CM; Barlow PM; Rice AL; Casey M; Simmons K; Pittenger G; Bastyr EJ; Wolka AM; Vinik AI
Diabetes Care; 2007 Apr; 30(4):896-902. PubMed ID: 17392551
[TBL] [Abstract][Full Text] [Related]
3. PKC inhibition and diabetic microvascular complications.
Clarke M; Dodson PM
Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):573-86. PubMed ID: 18054736
[TBL] [Abstract][Full Text] [Related]
4. Ruboxistaurin.
Taulien CA; Joy SV
Drugs Today (Barc); 2006 Sep; 42(9):577-85. PubMed ID: 17028667
[TBL] [Abstract][Full Text] [Related]
5. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial.
Vinik AI; Bril V; Kempler P; Litchy WJ; Tesfaye S; Price KL; Bastyr EJ;
Clin Ther; 2005 Aug; 27(8):1164-80. PubMed ID: 16199243
[TBL] [Abstract][Full Text] [Related]
6. A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C beta inhibition.
Tuttle KR; Anderson PW
Am J Kidney Dis; 2003 Sep; 42(3):456-65. PubMed ID: 12955673
[TBL] [Abstract][Full Text] [Related]
7. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy.
; Aiello LP; Davis MD; Girach A; Kles KA; Milton RC; Sheetz MJ; Vignati L; Zhi XE
Ophthalmology; 2006 Dec; 113(12):2221-30. PubMed ID: 16989901
[TBL] [Abstract][Full Text] [Related]
8. Protein kinase C-beta inhibition attenuates the progression of nephropathy in non-diabetic kidney disease.
Kelly DJ; Edgley AJ; Zhang Y; Thai K; Tan SM; Cox AJ; Advani A; Connelly KA; Whiteside CI; Gilbert RE
Nephrol Dial Transplant; 2009 Jun; 24(6):1782-90. PubMed ID: 19155535
[TBL] [Abstract][Full Text] [Related]
9. The role of protein kinase C activation and the vascular complications of diabetes.
Das Evcimen N; King GL
Pharmacol Res; 2007 Jun; 55(6):498-510. PubMed ID: 17574431
[TBL] [Abstract][Full Text] [Related]
10. Ruboxistaurin: LY 333531.
Drugs R D; 2007; 8(3):193-9. PubMed ID: 17472415
[TBL] [Abstract][Full Text] [Related]
11. Endothelial and neural regulation of skin microvascular blood flow in patients with diabetic peripheral neuropathy: effect of treatment with the isoform-specific protein kinase C beta inhibitor, ruboxistaurin.
Brooks B; Delaney-Robinson C; Molyneaux L; Yue DK
J Diabetes Complications; 2008; 22(2):88-95. PubMed ID: 18280438
[TBL] [Abstract][Full Text] [Related]
12. Protein kinase Cbeta inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointerstitial injury in advanced experimental diabetic nephropathy.
Kelly DJ; Chanty A; Gow RM; Zhang Y; Gilbert RE
J Am Soc Nephrol; 2005 Jun; 16(6):1654-60. PubMed ID: 15843473
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase C-beta inhibition for diabetic kidney disease.
Tuttle KR
Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S70-4. PubMed ID: 18977550
[TBL] [Abstract][Full Text] [Related]
14. [Protein kinase C beta-Inhibitor ruboxistaurin].
Musch A
Med Monatsschr Pharm; 2005 Aug; 28(8):292-3. PubMed ID: 16128544
[No Abstract] [Full Text] [Related]
15. Molecule of the month. Ruboxistaurin mesilate hydrate.
Drug News Perspect; 2003 Dec; 16(10):691. PubMed ID: 14747848
[No Abstract] [Full Text] [Related]
16. Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes.
Gilbert RE; Kim SA; Tuttle KR; Bakris GL; Toto RD; McGill JB; Haney DJ; Kelly DJ; Anderson PW
Diabetes Care; 2007 Apr; 30(4):995-6. PubMed ID: 17229944
[No Abstract] [Full Text] [Related]
17. PKC-B inhibition: a new therapeutic approach for diabetic complications?
Avignon A; Sultan A
Diabetes Metab; 2006 Jun; 32(3):205-13. PubMed ID: 16799396
[TBL] [Abstract][Full Text] [Related]
18. Ruboxistaurin: PKC-beta inhibition for complications of diabetes.
Danis RP; Sheetz MJ
Expert Opin Pharmacother; 2009 Dec; 10(17):2913-25. PubMed ID: 19929710
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients.
Aiello LP; Clermont A; Arora V; Davis MD; Sheetz MJ; Bursell SE
Invest Ophthalmol Vis Sci; 2006 Jan; 47(1):86-92. PubMed ID: 16384948
[TBL] [Abstract][Full Text] [Related]
20. Protein kinase C beta inhibitors: a new therapeutic target for diabetic nephropathy and vascular complications.
Budhiraja S; Singh J
Fundam Clin Pharmacol; 2008 Jun; 22(3):231-40. PubMed ID: 18485142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
